Abstract

A New Grammar for Drug Design: Rethinking Binding and Kinetics

Jose Duca, Head, Novartis Institute for Biomedical Research Inc

A new theory of binding that allows us to rethink drug discovery and design is being developed in our group. These novel concepts offer the potential to design molecules against a kinetic and/or binding profile. In this talk the general theory framework will be introduced and relevant examples to drug discovery will be discussed.